RxDoctor Payments Data

Joshua Dull

Nurse Practitioner · Hagerstown, MDNPI 1225523756

Payments from drug & device makers

$801in general payments, 2019–2025

Across 17 payments — averaging $47.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$215
  • Astellas Pharma US Inc$191
  • Axsome Therapeutics, Inc.$125
  • Boston Scientific$90
  • AbbVie$74
  • Teleflex LLC$63
  • plus $43 from 1 others

What the payments were for

  • Food & beverage$70788%
  • Education$9412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$801 in reported general payments places this provider in the 80th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$32,440
Medicare patients
236
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron113$73,799
OrgovyxRelugolix15$39,358
Methenamine Hippurate130$11,340
Tamsulosin Hcl567$10,199
Trospium Chloride ErTrospium Chloride42$5,491
Solifenacin Succinate95$4,124
Finasteride282$4,064
Oxybutynin Chloride ErOxybutynin Chloride122$3,673
Potassium Citrate ErPotassium Citrate17$3,006
Silodosin19$2,043
Dutasteride50$1,563
Amitriptyline Hcl57$887
Alfuzosin Hcl ErAlfuzosin Hcl42$793
Bethanechol Chloride19$711
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$191$73,799113 claims
Sumitomo Pharma America, Inc.Orgovyx$215$39,35815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →